Adamas Pharmaceuticals Inc.
| NASDAQ: ADMS | Healthcare / Drugs - Generic / USA |
| 6.20 | -0.2200 | -3.43% | Vol 201 654 | 1Y Perf -72.45% |
| Aug 19th, 2019 16:00 |
| BID | 6.19 | ASK | 6.20 | ||
| Open | 6.50 | Previous Close | 6.42 | ||
| Pre-Market | - | After-Trading | 6.18 | ||
| - -% | -0.02 -0.32% |
| Target Price | 13.29 | Analyst Rating | Moderate Buy 2.11 | |
| Potencial % | 114.36 | Finscreener Ranking | ★★★+ — - | |
| Insiders Trans % 3/6/12M | -100/-100/-73 | Value Ranking | — - | |
| Insiders Value % 3/6/12M | -100/-100/-36 | Growth Ranking | ★★+ 46.91 | |
| Insiders Shares Cnt. % 3/6/12M | -100/-100/-54 | Income Ranking | — - | |
| Market Cap (mil) | 172 | Earnings Rating | Strong Buy | |
| Price Range Ratio 52wk % | 10.44 | Earnings Date | 8th Aug 2019 |
Today's Price Range 6.156.66 | 52wk Range 4.2023.36 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.12% | ||
| 1 Month | 7.18% | ||
| 3 Months | 12.04% | ||
| 6 Months | -39.03% | ||
| 1 Year | -72.45% | ||
| 3 Years | -53.91% | ||
| 5 Years | -63.21% | ||
| 10 Years | - |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | -60.38 | |||
ROE last 12 Months | -107.65 | |||
Return on Assets (5Y Avg) | -24.76 | |||
ROA last 12 Months | -48.19 | |||
Return on Capital (5Y Avg) | -36.83 | |||
ROC last 12 Months | -46.91 | |||
Return on invested Capital Q | -13.24 | |||
Return on invested Capital Y | -60.63 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 5.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 2.63 | |||
PS Ratio | 4.99 | |||
Price to Cash Flow | 23.20 | |||
Price to Free Cash Flow | -2.50 | |||
Cash Flow Per Share | -3.68 | |||
Price to Tangible Book | 2.63 | |||
Book Value per Share | 2.30 | |||
Enterprise Value (in ths.) | 106 934 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | 6.60 | |||
Current Ratio | 7.00 | |||
Long Term Debt to Total Capital | 0.67 | |||
Total Debt to Equity | 2.03 | |||
Interest Coverage | -6.00 | |||
| Leverage Ratio | 3.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | 97.60 | |||
EBIT Margin | -249.50 | |||
EBITDA Margin | -246.20 | |||
Pre-tax Profit Margin | -5 965.50 | |||
Profit Margin | - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (in ths.) | 35 593 | |||
Revenue per Share | 1.28 | |||
Revenue Growth 3 Years | 184.40 | |||
Revenue Growth 5 Years | -28.15 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2019 | -0.98 | -0.90 | 8.16 |
| Q01 2019 | -1.13 | -1.08 | 4.42 |
| Q04 2018 | -1.36 | -1.06 | 22.06 |
| Q03 2018 | -1.34 | -1.22 | 8.96 |
| Q02 2018 | -1.41 | -1.26 | 10.64 |
| Q01 2018 | -1.38 | -1.35 | 2.17 |
| Q04 2017 | -1.15 | -1.27 | -10.43 |
| Q03 2017 | -1.03 | -1.04 | -0.97 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2019 QR | -0.89 | 6.32 | Positive |
| 12/2019 QR | -0.84 | 7.69 | Positive |
| 12/2019 FY | -3.74 | 3.36 | Positive |
| 12/2020 FY | -2.39 | -3.02 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.98 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 201 654 |
| Shares Outstanding (in ths.) | 27 771 |
| Trades Count | 3 634 |
| Dollar Volume | 5 157 781 |
| Avg. Volume | 454 772 |
| Avg. Weekly Volume | 388 601 |
| Avg. Monthly Volume | 350 455 |
| Avg. Quarterly Volume | 351 322 |
Adamas Pharmaceuticals Inc.
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
CEO: Gregory T. Went
Teplephone: +1 510 450-3500
Address: 1900 Powell Street, Emeryville 94608, CA, USA
